Eliot Forster, F-star CEO (Rachel Kiki for Endpoints News)

F-star's sale to Chi­nese buy­er cleared by CFIUS fol­low­ing months of holdup

Af­ter tak­ing sev­er­al months to re­view F-star’s pro­posed sale to a Chi­nese com­pa­ny, the US gov­ern­ment’s Com­mit­tee on For­eign In­vest­ment in the Unit­ed States (CFIUS) has fi­nal­ly giv­en its bless­ing for the deal.

The clear­ance comes al­most nine months af­ter in­voX Phar­ma, a sub­sidiary of Chi­na’s Sino Bio­pharm, first struck a deal to buy out F-star for $161 mil­lion in cash.

CFIUS is a long­stand­ing group tasked with scru­ti­niz­ing trans­ac­tions in­volv­ing for­eign in­vest­ments in the US and block­ing any deals it deems threat­en­ing. But in re­cent years, the White House has sig­naled that biotech could be a top area for crack­down, trig­ger­ing fears that it would cre­ate road­blocks for Asian in­vestors in­ter­est­ed in US com­pa­nies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.